
    
      The main purpose of this prospective study is to demonstrate the therapeutic equivalence of
      topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic
      suspension 1%) dosed three times daily in IOP reduction in patients with POAG or OH.
    
  